{"id":908538,"date":"2025-11-11T13:51:20","date_gmt":"2025-11-11T18:51:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\/"},"modified":"2025-11-11T13:51:20","modified_gmt":"2025-11-11T18:51:20","slug":"class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\/","title":{"rendered":"CLASS ACTION REMINDER: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Lawsuit by December 15, 2025"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n PHILADELPHIA<\/span>
\n <\/span>, Nov. 11, 2025<\/span><\/span> \/PRNewswire\/ —\u00a0National plaintiffs’ law firm Berger Montague PC<\/span><\/a><\/u>\u00a0announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX)<\/b> (“MoonLake” or the “Company”) on behalf of investors who purchased MoonLake shares during the period of\u00a0March 10, 2024<\/span> through September 29, 2025<\/span><\/b>(the “Class Period”).<\/p>\n

\n

\n
\n \"A
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n
\n Investor Deadline:<\/i>
\n <\/b>
\n Investors who purchased MoonLake\u00a0securities during the Class Period may, no later than December 15, 2025<\/span><\/b>, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,<\/i>\u00a0CLICK HERE<\/a><\/u><\/b>.<\/p>\n

MoonLake is a biopharmaceutical company headquartered in Zug, Switzerland<\/span>, specializing in therapies for inflammatory diseases.<\/p>\n

According to the complaint, the Company misled investors by aggressively touting its sole drug candidate,\u00a0sonelokimab (SLK), as clinically superior to competing therapies due to its Nanobody structure. However, the lawsuit alleges<\/span> that\u00a0the Company failed to disclose that SLK targets the same molecules as FDA-approved BIMZELX and offered no demonstrated clinical advantage.<\/p>\n

According to the complaint, on\u00a0September 28, 2025, the Company revealed\u00a0Phase 3 clinical trial data showing SLK failed to match BIMZELX’s efficacy. Analysts reportedly labeled the outcome as “disastrous,” and the Company’s stock\u00a0collapsed by $55.75<\/span> per share \u2013 nearly 90%<\/i><\/b> \u2013 in one trading day.<\/p>\n

\n
\n If you are a MoonLake investor and would like to learn more about this action, <\/i>
\n <\/b>
\n
\n
\n
\n CLICK HERE<\/a>
\n <\/u>
\n <\/i>
\n <\/b>\u00a0or please contact Berger Montague<\/span>: Andrew Abramowitz<\/span> at <\/i><\/b>aabramowitz@bergermontague.com<\/a><\/u><\/i><\/b> or (215) 875-3015, or Caitlin Adorni<\/span> at <\/i><\/b>cadorni@bergermontague.com<\/a><\/u><\/i><\/b> or (267)764-4865.<\/i><\/b><\/p>\n

\n About Berger Montague<\/span>
<\/b>
\n Berger Montague<\/span>, with offices in Philadelphia<\/span>, Minneapolis<\/span>, Delaware<\/span>, Washington, D.C.<\/span>, San Diego<\/span>, San Francisco<\/span>, Chicago<\/span>, Malvern, PA<\/span>, and Toronto<\/span> has been a pioneer in securities class action litigation<\/a><\/u>\u00a0since its founding in 1970. Berger Montague<\/span> has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States<\/span>.<\/p>\n

\n For more information or to discuss your rights, please contact:
<\/b>
\n Andrew Abramowitz<\/span>
\n
\n Senior Counsel
<\/i>
\n Berger Montague<\/span>
\n
(215) 875-3015
aabramowitz@bergermontague.com<\/a><\/p>\n

\n Caitlin Adorni<\/span>
\n
\n Director of Portfolio & Institutional Client Monitoring Services
<\/i>
\n Berger Montague<\/span>
\n
(267) 764-4865
cadorni@bergermontague.com<\/a><\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025-302611889.html<\/a><\/p>\n

SOURCE Berger Montague<\/span><\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire PHILADELPHIA , Nov. 11, 2025 \/PRNewswire\/ —\u00a0National plaintiffs’ law firm Berger Montague PC\u00a0announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”) on behalf of investors who purchased MoonLake shares during the period of\u00a0March 10, 2024 through September 29, 2025(the “Class Period”). Investor Deadline: Investors who purchased MoonLake\u00a0securities during the Class Period may, no later than December 15, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,\u00a0CLICK HERE. MoonLake is a biopharmaceutical company headquartered in Zug, Switzerland, specializing in therapies for inflammatory diseases. According to the complaint, the Company misled investors by aggressively touting its sole drug candidate,\u00a0sonelokimab (SLK), as clinically superior to competing therapies due … <\/p>\n

Continue reading “CLASS ACTION REMINDER: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Lawsuit by December 15, 2025”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-908538","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCLASS ACTION REMINDER: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Lawsuit by December 15, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CLASS ACTION REMINDER: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Lawsuit by December 15, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire PHILADELPHIA , Nov. 11, 2025 \/PRNewswire\/ —\u00a0National plaintiffs’ law firm Berger Montague PC\u00a0announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”) on behalf of investors who purchased MoonLake shares during the period of\u00a0March 10, 2024 through September 29, 2025(the “Class Period”). Investor Deadline: Investors who purchased MoonLake\u00a0securities during the Class Period may, no later than December 15, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,\u00a0CLICK HERE. MoonLake is a biopharmaceutical company headquartered in Zug, Switzerland, specializing in therapies for inflammatory diseases. According to the complaint, the Company misled investors by aggressively touting its sole drug candidate,\u00a0sonelokimab (SLK), as clinically superior to competing therapies due … Continue reading "CLASS ACTION REMINDER: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Lawsuit by December 15, 2025"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-11T18:51:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CLASS ACTION REMINDER: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Lawsuit by December 15, 2025\",\"datePublished\":\"2025-11-11T18:51:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\\\/\"},\"wordCount\":359,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\\\/\",\"name\":\"CLASS ACTION REMINDER: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Lawsuit by December 15, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"datePublished\":\"2025-11-11T18:51:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CLASS ACTION REMINDER: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Lawsuit by December 15, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CLASS ACTION REMINDER: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Lawsuit by December 15, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\/","og_locale":"en_US","og_type":"article","og_title":"CLASS ACTION REMINDER: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Lawsuit by December 15, 2025 - Market Newsdesk","og_description":"PR Newswire PHILADELPHIA , Nov. 11, 2025 \/PRNewswire\/ —\u00a0National plaintiffs’ law firm Berger Montague PC\u00a0announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”) on behalf of investors who purchased MoonLake shares during the period of\u00a0March 10, 2024 through September 29, 2025(the “Class Period”). Investor Deadline: Investors who purchased MoonLake\u00a0securities during the Class Period may, no later than December 15, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,\u00a0CLICK HERE. MoonLake is a biopharmaceutical company headquartered in Zug, Switzerland, specializing in therapies for inflammatory diseases. According to the complaint, the Company misled investors by aggressively touting its sole drug candidate,\u00a0sonelokimab (SLK), as clinically superior to competing therapies due … Continue reading \"CLASS ACTION REMINDER: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Lawsuit by December 15, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-11T18:51:20+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CLASS ACTION REMINDER: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Lawsuit by December 15, 2025","datePublished":"2025-11-11T18:51:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\/"},"wordCount":359,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\/","name":"CLASS ACTION REMINDER: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Lawsuit by December 15, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","datePublished":"2025-11-11T18:51:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/class-action-reminder-berger-montague-advises-moonlake-immunotherapeutics-nasdaq-mltx-investors-to-inquire-about-a-securities-fraud-lawsuit-by-december-15-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CLASS ACTION REMINDER: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Lawsuit by December 15, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/908538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=908538"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/908538\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=908538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=908538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=908538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}